Statin use does not prevent recurrent adenomatous polyp formation in a VA population

Indian J Gastroenterol. 2010 Jun;29(3):106-11. doi: 10.1007/s12664-010-0032-1. Epub 2010 Jul 25.


Purpose: To evaluate whether statin use was associated with recurrent adenomatous polyps.

Methods: We conducted a retrospective cohort study. We used electronic health records to evaluate veterans who underwent polypectomy between January 1, 1999 and December 31, 2001 and surveillance colonoscopy by December 2006. We obtained data on pathology, demographics, body mass index, comorbidity, habits, family history, and medications. We used multivariate proportional hazards regression models to analyze data.

Results: We evaluated 197 eligible patients from among 821 who underwent colonoscopy during this period; their mean (SD) age was 63.1 (8.8) years, 192 (98%) were men, and 80 (41%) non-Hispanic white. Surveillance colonoscopy was performed after a mean (SD) 1207 (452) days and 108 (55%) patients had recurrent adenomas. During follow-up, 88 (47%) of patients received statins, but use was not protective against recurrent adenomas (hazard ratio = 1.36, 95% CI 0.35-8.27). Only number of polyps at initial colonoscopy predicted recurrent adenomas (1.98, 95% CI 1.27-3.08).

Conclusions: The use of statins was not protective against the recurrence of adenomatous polyps.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenomatous Polyposis Coli / epidemiology
  • Adenomatous Polyposis Coli / prevention & control*
  • Adenomatous Polyposis Coli / surgery
  • Colonoscopy
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / prevention & control*
  • Poisson Distribution
  • Proportional Hazards Models
  • Retrospective Studies
  • Statistics, Nonparametric
  • Treatment Outcome
  • Veterans*


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors